FOR IMMEDIATE RELEASE
Media Contacts
[email protected]
410-576-7009
Consumers Who Bought Certain Generic Prescription Drugs in the United States Between May 1, 2009, and December 31, 2019, Could be Eligible for Compensation
BALTIMORE, MD (July 15, 2026) – Attorney General Anthony G. Brown today joined a coalition of 48 states and territories announcing a $29.6 million settlement with Glenmark to resolve allegations that the generic drug manufacturer engaged in a widespread, long-running conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade with regard to numerous generic prescription drugs.
As part of the settlement agreement, Glenmark will cooperate in the ongoing multistate litigations against 33 corporate defendants and 25 individual executives. The company has further agreed to an injunctive relief period of at least seven years. During this period, Glenmark will maintain an antitrust compliance program, report any potential antitrust violations directly to the attorneys general, and adopt a series of internal reforms to ensure fair competition and compliance with antitrust laws. Maryland’s share of today’s settlement is $178,000.
“For years, Glenmark colluded to drive up prices for drugs that are meant to be an affordable option, forcing Marylanders to pay inflated prices for medications they depend on,” said Attorney General Brown. “This settlement provides monetary relief for those Marylanders and requires Glenmark to reform its conduct so competition, not collusion, sets the price Marylanders pay.”
The Glenmark settlement follows multistate settlements with Lannett, Bausch, Apotex and Heritage totaling $66.95 million. This latest settlement comes as the states prepare for the first trial to be held in Hartford, Connecticut and anticipated to be scheduled in early 2027.
If you purchased a generic prescription drug manufactured by either Glenmark, Lannett, Bausch, Apotex or Heritage between May 2009 and December 2019, you may be eligible for compensation. To determine your eligibility, call 1-866-290-0182 (Toll-Free), email [email protected] or visit www.AGGenericDrugs.com.
The Maryland Office of the Attorney General is part of a coalition of nearly all states and territories having filed a series of antitrust cases, starting in 2016. The first complaint included Heritage and 17 other corporate defendants, two individual defendants, and 15 generic drugs. Two former executives from Heritage Pharmaceuticals, Jeffery Glazer and Jason Malek, have since entered into settlement agreements and are cooperating. The second complaint was filed in 2019 against Teva Pharmaceuticals and 21 of the nation’s largest generic drug manufacturers. The complaint names 16 individual senior executive defendants. The third complaint, to be tried first, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and names 26 corporate defendants and 10 individual defendants. Seven additional pharmaceutical executives have been cooperating to support the states’ claims.
The cases all stem from a series of investigations built on evidence from several cooperating witnesses at the core of the different conspiracies, a massive document database of over 20 million documents, and a phone records database containing millions of call detail records and contact information for over 600 sales and pricing individuals in the generics industry. Each complaint addresses a different set of drugs and defendants, and lays out an interconnected web of competing industry executives that met with each other during industry dinners and outings, and communicated via frequent telephone calls, emails and text messages that sowed the seeds for their unlawful agreements. Throughout the complaints, defendants use terms like “fair share,” “playing nice in the sandbox,” and “responsible competitor” to describe how they unlawfully discouraged competition, raised prices, and enforced an ingrained culture of collusion. Among the records obtained by the states is a two-volume notebook containing the contemporaneous notes of one of the states’ cooperators that memorialized his discussions during phone calls with competitors and internal company meetings over a period of several years.
Joining Attorney General Brown in today’s settlement with Glenmark include the states and territories of Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, U.S. Virgin Islands, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, and Puerto Rico.
###